Daily Journal Staff Writer
SAN DIEGO - Amylin Pharmaceuticals Inc. and Eli Lilly and Co. announced a settlement Tuesday that will resolve a lawsuit stemming from the companies' collaboration on a diabetes drug called exenatide.
Amylin filed suit after Lilly announced plans to market two new diabetes drugs developed by the German pharmaceutical company Boehringer Ingelheim. Amylin said Boehringer's Tradjenta would be a ...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In